Gilead VP Jared Baeten promises lenacapavir will be available for generic production & promises Gilead will meanwhile make available at “access price” at high volumes; but says “low income” settings, doesn’t mention “middle income”, & names no price, no volume & no generic firms!

and makes no commitment to Medicines Patent Pool! UNAIDS urges Gilead to work with Medicines Patent Pool, to include all middle as well as low income countries, & to name a price that has to be under $100 per person per year. Andrew Hill’s paper at AIDS2024 says $40 is possible.

.@wiessner_peter asks Gilead VP “Jared, you said access for low income, was that a mistake? did you mean low ***and middle income? *** you mentioned volume, price & generic firms. what is the volume?what is the price? who are the generic firms?” Gilead gives no clear answer.

@wiessner_peter Guardian’s @katlay asks Gilead if generic licensing will go to middle income countries too, Gilead replies list still being finalised. Lay asks if on current draft list there are any middle income countries. Gilead refuses to say, says list still not decided.

Such nonsense word salad from @GileadSciences. GLD uses taxpayer $ to develop this drug. Then charges the highest price to taxpayer funded drug programs in the U.S. Medicare, Medicaid, Tricare, Veterans Administration. Then hands out $ to executives and shareholders.